ADC Target Prediction Service
Antibody-drug conjugates (ADCs) have become a key therapeutic modality in oncology, spurred by superior clinical profiles compared to standard-of-care chemotherapy across multiple indications. In the drug development process, it is crucial to identify targets suitable for ADC development. CD ComputaBio's service aims to bridge the gap between complex biological research and efficient drug development by leveraging advanced computational algorithms and vast biological databases.
Introduction to ADC and its Target Prediction
Antibody–drug conjugate (ADC) is typically composed of a monoclonal antibody (mAbs) covalently attached to a cytotoxic drug via a chemical linker. Target prediction involves identifying cell surface antigens that are highly expressed on cancer cells but have limited expression on normal tissues. This process is complex, and computer-based computational methods using advanced computational algorithms combined with comprehensive genomic, proteomic and clinical data can predict promising ADC targets with relative accuracy.
Figure 1. The core components and mechanism of antibody–drug conjugates (ADCs).(Li K, et al., 2023)
Our Services
In the intricate process of polyclonal antibody design, the ADC target prediction service emerges as a cornerstone, offering a suite of advanced and indispensable services. These services are not only integral to the development of high-quality polyclonal antibodies but also serve as catalysts for innovation in the biopharmaceutical field.
ADC Target Prediction Service
ADC target prediction service aims to accurately locate the tumor targets of drug action and help develop more effective anti-cancer drugs. Our service uses bioinformatics analysis and machine learning algorithms to deeply analyze the molecular characteristics of tumor cells and disease mechanisms and screen potential targets.
Target Validation Services
Computational methods such as molecular docking simulations and molecular dynamics simulation services are used to perform in silico validation of predicted targets. This helps understand the binding affinity of the antibody to the target antigen and the potential impact of ADC binding on the target's biological function.
Workflow of ADC Target Prediction
Database Establishment: Store the data of drug targets and their corresponding ligands in the database, and generate a three-dimensional conformation of the ADC molecular structure based on the molecular force field.
Structure Generation: According to the corresponding molecular force field, use molecular docking and virtual screening to make predictions.
Target Prediction: Calculate the matching degree based on the analysis results, output the data of drug targets corresponding to ligands whose matching degree exceeds the preset threshold, and obtain a list of drug targets for the molecules to be predicted.
Advanced Methods
CD ComputaBio provides advanced ADC target prediction services to meet the various needs of our customers. These methods are designed to handle molecules with various ADC drugs:
- Molecular Docking Service
- Virtual Screening Service
- Molecular Dynamics Simulation Service
- More
Advantages
- Team of experts: Our services are supported by a team of experienced scientists and researchers with a proven track record in ADC target predictions. Their expertise ensures the highest quality of analysis and data interpretation.
- Timely and efficient service: We understand the importance of time in research and drug development. Our services are designed to deliver timely and efficient results, allowing you to accelerate your project.
CD ComputaBio' target prediction service can significantly reduce the cost and labor of the subsequent experiments. Our service is a personalized and customized innovative scientific research service. Each project needs to be evaluated before the corresponding analysis plan and price can be determined. If you are interested in our services or have any questions, please feel free to contact us.
Reference:
- Li K, Xie G, Deng X, et al. Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives. Frontiers in Oncology, 2023, 13: 1259784.
* For Research Use Only.
Related Services
